Peter Marks could have given Sarepta a narrower approval — instead of approving it for nearly all patients. But that proved not to be the case, writes Matthew Herper. https://trib.al/LQsa6Bp
STAT’s Post
More Relevant Posts
-
Stay cool with the latest edition of "Weekly Update!" We have not one but two STAT investigations - plus, biotech updates, Fauci on the First Opinion podcast, Elmo and friends, and much more! Read now ⬇
Two STAT Investigations, biotech updates, Fauci on the podcast, Elmo and friends, and much more!
STAT on LinkedIn
To view or add a comment, sign in
-
CTE can only be diagnosed after death. But Ann McKee and her colleagues published new research this year that could eventually help identify the condition while people are still alive. She spoke to STAT in a new Q/A. https://trib.al/HZi08Eo
The biggest misconception about CTE, according to a leading brain trauma expert
https://www.statnews.com
To view or add a comment, sign in
-
Nominations for the 2024 #STATWunderkinds close tomorrow! Last call to make a submission: https://trib.al/S7F6AMi
To view or add a comment, sign in
-
-
Medicare regulators proposed new codes that support payment for digital mental health treatments. https://trib.al/kycqy5h
Medicare proposes to cover some digital therapies in a breakthrough for health tech firms
https://www.statnews.com
To view or add a comment, sign in
-
Cancer studies fail all the time. But it’s far less common, and quite alarming, to see a study in which the experimental drug showed “reduced efficacy” (Roche’s terminology) in relation to a comparator, Adam Feuerstein writes. Simply stated: The patients fared meaningfully worse. Read more in Adam’s Biotech Scorecard. https://trib.al/J4lnm0l
Roche’s TIGIT study was a bust. What's the outlook for its next big bet?
https://www.statnews.com
To view or add a comment, sign in
-
Pfizer plans to advance a new, once-a-day formulation of its experimental obesity drug danuglipron, meant to be a pill version in the same class as Wegovy and Zepbound. https://trib.al/JzUXv7i
Pfizer says it will advance once-daily GLP-1 pill after all
https://www.statnews.com
To view or add a comment, sign in
-
The FDA rejected Novo Nordisk’s weekly insulin for the treatment of diabetes. https://trib.al/fJZb1j8
Novo Nordisk’s weekly insulin rejected by FDA
https://www.statnews.com
To view or add a comment, sign in
-
The Federal Trade Commission plans to sue the three largest PBMs. Here's why: https://trib.al/psBpzZC
FTC plans to sue PBMs over the high cost of insulin and other medicines
https://www.statnews.com
To view or add a comment, sign in
-
The federal government will not modify regulations that dictate how hospitals publish their prices for consumers. https://trib.al/dWyrGEG
Biden administration ignores calls to bolster hospital price transparency
https://www.statnews.com
To view or add a comment, sign in
-
Fourth time’s the charm? Sanford Health hopes to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system. https://trib.al/33w87Qi
Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system
https://www.statnews.com
To view or add a comment, sign in
More from this author
-
Two STAT Investigations, biotech updates, Fauci on the podcast, Elmo and friends, and much more!
STAT 2d -
Debate recap, SCOTUS decisions, gun violence, bird flu, and more.
STAT 2w -
STAT's investigation on coercive sterilizations. Plus, a biotech's hope for heart disease, a warning label on social media, extreme heat, and more.
STAT 3w